PATENT CLAIM ANALYSIS

Application Number: 15900660
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["544", "256000"]

Abstract:
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Claim (Index 58):
The crystalline form of  claim 56 , wherein the crystalline form is unsolvated.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 88.0
- Lexical Diversity: 1.54688
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15497896', '15670614', '13908949', '14405317', '15386118']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8448288410222989
- 35 USC 102 Novelty (BERT): 0.6044765162146599
- Combined Prediction Score: 0.820793608541535
- Mean Citation Score: 601.5469639999999
- Max Citation Score: 637.139
- Similarity Product: 475.5175594149828

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test